HAVANA, Cuba, Sep 8 (ACN) The Cuban vaccine against SARS-CoV-2, Soberana 01, is included in the coronavirus vaccines tracker of the American newspaper The New York Times.
This tracker is an interactive tool in a web environment that contains all those vaccine candidates that have reached human trials, along with a selection of other promising ones that are still being tested in cells or animals, according to Infomed website.
With September 4, 2020 as the last update date so far, the Tracker reports that globally researchers are testing 37 vaccines in human clinical trials, and at least 91 preclinical vaccines are under active animal research.
The work for Soberana 01 began in January 2020 with the decipherment of the SARS-CoV-2 genome, and the first human vaccine safety trials began last March.
Soberana 01 is the 30th vaccine candidate in the world and the first in Latin America and the Caribbean to receive authorization for clinical trials, which is a reflection of the hard work of Cuban scientists.
The first phase of the clinical trials for its definitive validation began on August 24 with the administration of the product to 20 volunteers, aged between 19 and 59 years.
It was recently applied to individuals between the ages of 60 and 80, and in general, the vaccine has shown no adverse effects in volunteers, only brief pain at the injection site, something common to all vaccines.
According to the BioCubaFarma group, if the clinical trials yield the results desired by the creators, there is already a strategy for the large-scale manufacture of what would then be, officially, the Cuban vaccine against COVID-19.